What action is HHS taking?
• Seeking rapid public comment on the new evidence on health risks associated with ephedra to establish an up-to-date record as quickly as possible to support new restrictions on ephedra-containing products. • Seeking rapid public comment on whether the currently available evidence and medical literature present a “significant or unreasonable risk of illness or injury” from dietary supplements containing ephedra. • Seeking rapid comment on a strong new warning label on any ephedra products that continue to be marketed. • Immediately executing a series of actions against ephedra products making unsubstantiated claims about sports performance enhancement. • In seeking the 30-day public comment period, FDA is reopening a proposed rule entitled “Dietary Supplements Containing Ephedrine Alkaloids,” which would have required a warning statement for these products, as well as restrictions on their potency and composition. FDA later withdrew parts of this proposed rule because of concerns abou
